BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
TargeGen initiates Phase II clinical trial of topically-applied drug for age-related macular degeneration
News | 07. 30. 2007
TargeGen
TargeGen, Inc. today announced that the Company has initiated a multi-center Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).
